ClinicalTrials.gg

Program

Platinum Compounds

Also written as “QLS5132; Platinum; Bevacizumab”, “HS-10502 + Platinum + Bevacizumab” and “Platinum”.

Its studies are mostly in Stomach Neoplasms · Ovarian Neoplasms · Small Cell Lung Carcinoma · Carcinoma, Non-Small-Cell Lung · Head and Neck Neoplasms, led by 5 companies.

Furthest: phase 3, since Jun 24, 20165 company-led studies, 2 open or runningNext primary completion: Apr 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb10 open or runningphase 1since Jun 24, 2016Jun 24, 2016none ahead
Eli Lilly10 open or runningphase 2since Jun 1, 2005Jun 1, 2005none ahead
Hansoh Pharmaceutical Group11 open or runningphase 1since Jan 7, 2025Jan 7, 2025none ahead
Merck KGaA, Darmstadt, Germany10 open or runningphase 3since Jul 19, 2005Jul 19, 2005none ahead
Qilu Pharmaceutical11 open or runningphase 2since Mar 1, 2026Mar 1, 2026Apr 2027phase 2 · NCT07453394

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 1, 2005First study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Eli LillyEli Lilly · NCT00112346 · 120 enrolled · United States, Canada
  2. Jul 19, 2005Merck KGaA, Darmstadt, Germany's first study: phase 3 study in Head and Neck NeoplasmsNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT00122460 · 442 enrolled · Austria, Belgium, Czech Republic and more
  3. Jun 24, 2016Bristol-Myers Squibb's first study: phase 1 study in Small Cell Lung CarcinomaNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT02815592 · 12 enrolled · Spain
  4. Jan 7, 2025Hansoh Pharmaceutical Group's first study: phase 1 study in Ovarian NeoplasmsNew to Hansoh Pharmaceutical GroupHansoh Pharmaceutical Group · NCT06769425 · 157 planned · China
  5. Mar 1, 2026Qilu Pharmaceutical's first study: phase 2 study in Stomach NeoplasmsNew to Qilu PharmaceuticalQilu Pharmaceutical · NCT07453394 · 626 planned

Ahead

  1. Apr 2027Primary completion: phase 2 study in Stomach NeoplasmsQilu Pharmaceutical · NCT07453394

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07453394Stomach Neoplasms2Not yet recruitingQilu PharmaceuticalApr 2027626
NCT06769425Ovarian Neoplasms · China1RecruitingHansoh Pharmaceutical GroupMay 7, 2026157
NCT02815592Small Cell Lung Carcinoma · Spain1CompletedBristol-Myers SquibbDec 15, 201912
NCT00122460Head and Neck Neoplasms · Austria, Belgium, Czech Republic and more3CompletedMerck KGaA, Darmstadt, GermanyMar 2007442
NCT00112346Carcinoma, Non-Small-Cell Lung · United States, Canada2CompletedEli LillyDec 2006120

How it is read

Names in the registry

  • “QLS5132; Platinum; Bevacizumab”, 1 entry
  • “HS-10502 + Platinum + Bevacizumab”, 1 entry
  • “Platinum”, 1 entry
  • “Cetuximab + platinum + gemcitabine”, 1 entry
  • “Platinum + Gemcitabine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.